OncoMatch/Clinical Trials/NCT06451211
Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer
Is NCT06451211 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Tislelizumab and Oxaliplatin for stomach neoplasms.
Treatment: Tislelizumab · Oxaliplatin · S-1 · Capecitabine — The aim of this study is to test the efficacy and safety of immunotherapy plus chemotherapy on people with a relatively rare type of gastric cancer. Participants will take the anti-PD-1 inhibitor (Tislelizumab) and platinum-based chemotherapy (oxaliplatin + capecitabine or oxaliplatin + S-1) in a 3-week cycle, followed by a radical operation after 6 cycles.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Gastric Cancer
Disease stage
Required: Stage CT1-2N+M0, CT3-4NANYM0
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: cytotoxic chemotherapy
Previous cytotoxic chemotherapy
Cannot have received: radiation therapy
Previous...radiotherapy
Cannot have received: immunotherapy
Previous...immunotherapy
Lab requirements
Blood counts
white blood cell count > 4*10^9/l, neutrophil cell count > 1.5*10^9/l, hemoglobin > 90 g/l, platelet count > 100*10^9 /l
Kidney function
creatinine ≤ 1.5 ×uln or serum clearance > 60 ml/min
Liver function
serum bilirubin ≤ 1.5×uln, ast, alt ≤ 2.5×uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06451211 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage CT1-2N+M0 or CT3-4NANYM0 is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages